EMA — authorised 8 August 2018
- Marketing authorisation holder: BAXALTA INNOVATIONS GMBH
- Status: approved
EMA authorised Vonvendi on 8 August 2018
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. EMA authorised it on 8 August 2018.
BAXALTA INNOVATIONS GMBH holds the EU marketing authorisation.